Dataset Information


Trichostatin A inhibits the activation of Hepatic stellate cells by Increasing C/EBP-? Acetylation in vivo and in vitro.

ABSTRACT: Reversal of activated hepatic stellate cells (HSCs) to a quiescent state and apoptosis of activated HSCs are key elements in the reversion of hepatic fibrosis. CCAAT/enhancer binding protein ? (C/EBP-?) has been shown to inhibit HSC activation and promote its apoptosis. This study aims to investigate how C/EBP-? acetylation affects the fate of activated HSCs. Effects of a histone deacetylation inhibitor trichostatin A (TSA) on HSC activation were evaluated in a mouse model of liver fibrosis caused by carbon tetrachloride (CCl4) intoxication. TSA was found to ameliorate CCl4-induced hepatic fibrosis and improve liver function through increasing the protein level and enhancing C/EBP-? acetylation in the mouse liver. C/EBP-? acetylation was determined in HSC lines in the presence or absence of TSA, and the lysine residue K276 was identified as a main acetylation site in C/EBP-? protein. C/EBP-? acetylation increased its stability and protein level, and inhibited HSC activation. The present study demonstrated that C/EBP-? acetylation increases the protein level by inhibiting its ubiquitination-mediated degradation, and may be involved in the fate of activated HSCs. Use of TSA may confer an option in minimizing hepatic fibrosis by suppressing HSC activation, a key process in the initiation and progression of hepatic fibrosis.


PROVIDER: S-EPMC5849734 | BioStudies | 2018-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7016006 | BioStudies
2016-01-01 | S-EPMC5192182 | BioStudies
1000-01-01 | S-EPMC6170444 | BioStudies
2014-01-01 | S-EPMC4188519 | BioStudies
1000-01-01 | S-EPMC6023793 | BioStudies
2020-01-01 | S-EPMC7244173 | BioStudies
2018-01-01 | S-EPMC5817100 | BioStudies
2020-01-01 | S-EPMC7479613 | BioStudies
2015-01-01 | S-EPMC4543529 | BioStudies
1000-01-01 | S-EPMC5489887 | BioStudies